Breaking Down SG&A Expenses: Verona Pharma plc vs Perrigo Company plc

SG&A Expenses: Verona Pharma vs. Perrigo

__timestampPerrigo Company plcVerona Pharma plc
Wednesday, January 1, 20146752000001802274
Thursday, January 1, 20157718000002512761
Friday, January 1, 201612055000002894488
Sunday, January 1, 201711465000008096274
Monday, January 1, 201811258000007985229
Tuesday, January 1, 201911661000008994597
Wednesday, January 1, 2020117550000029772000
Friday, January 1, 2021111140000033907000
Saturday, January 1, 2022121010000026579000
Sunday, January 1, 2023127460000049868547
Loading chart...

Unlocking the unknown

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A expenses of Verona Pharma plc and Perrigo Company plc from 2014 to 2023. Perrigo, a well-established player, consistently reported higher SG&A expenses, peaking at approximately $1.27 billion in 2023. This represents a 47% increase from 2014, reflecting its expansive operations and market reach. In contrast, Verona Pharma, a smaller entity, saw its SG&A expenses grow significantly, from around $1.8 million in 2014 to nearly $50 million in 2023, marking a staggering 2,670% increase. This growth underscores Verona's aggressive expansion and investment in its operations. The contrasting trajectories of these companies highlight the diverse strategies in the pharmaceutical industry, where scale and growth ambitions shape financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025